
George Lundberg, MD Editor in Chief at Cancer Commons
-
July 28, 2021
New Chronic Lymphocytic Leukemia Treatments 2021 Bookmark
George Lundberg, MDTheSocialMedwork outlines several new drugs for treating chronic lymphocytic leukemia, including Brukinsa (zanubrutinib).
.
-
July 28, 2021
Latest Advances in the Management of Classical Hodgkin Lymphoma: The Era of Novel Therapies Bookmark
George Lundberg, MDThis academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.
.
-
July 28, 2021
New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment Bookmark
George Lundberg, MDReported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).
.
-
July 28, 2021
Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma Bookmark
George Lundberg, MDOncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.
.
.
-
July 28, 2021
2021 ASCO Annual Meeting Bookmark
George Lundberg, MDResearchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.
.
-
July 28, 2021
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer Bookmark
George Lundberg, MDAs reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.
.
-
July 28, 2021
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Bookmark
George Lundberg, MDOn May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.
.
-
July 28, 2021
Advances in Colorectal Cancer Research Bookmark
George Lundberg, MDThis outline from the National Cancer Institute covers recent research on colorectal cancer.
.
-
May 30, 2021
Cancer Support for LGBTQIA Patients Is Missing Bookmark
George Lundberg, MDThis piece from ASCO Connection outlines the need for and a path to improvement in cancer care for LGBTQIA patients.
.
-
May 4, 2021
Hepatocellular Carcinoma (HCC)—An Overview Bookmark
George Lundberg, MDOverview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:
This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)
.